Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

他のバージョン（1件）を表示する

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

書誌詳細
主要な著者:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
フォーマット:	Journal article
言語:	English
出版事項:	2008

類似資料

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
著者:: Clerico, M, 等
出版事項: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
著者:: Clerico, M, 等
出版事項: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
著者:: Clerico, M, 等
出版事項: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
著者:: Clerico, M, 等
出版事項: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
著者:: Clerico, M, 等
出版事項: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
著者:: Valéria Coelho Santa Rita Pereira, 等
出版事項: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
著者:: Clerico, M, 等
出版事項: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
著者:: Clerico, M, 等
出版事項: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
著者:: GJ Melendez-Torres, 等
出版事項: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
著者:: E.J. Ramos González, 等
出版事項: (2021-05-01)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
著者:: Andrew F Tyler, 等
出版事項: (2013-01-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
著者:: Clerico, M, 等
出版事項: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
著者:: Clerico, M, 等
出版事項: (2006)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
著者:: Joanna Roskal-Wałek, 等
出版事項: (2021-09-01)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
著者:: N. Y. Lasch
出版事項: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
著者:: Katarzyna Kapica-Topczewska, 等
出版事項: (2019-01-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
著者:: G. J. Melendez-Torres, 等
出版事項: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
著者:: G. Ya. Shvarts
出版事項: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
著者:: Özlem Taşkapılıoğlu, 等
出版事項: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
著者:: Özlem Taşkapılıoğlu, 等
出版事項: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
著者:: Oscar Fernández
出版事項: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
著者:: Massimiliano Mirabella, 等
出版事項: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
著者:: Mikhail Melnikov, 等
出版事項: (2020-01-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
著者:: Oscar Fernández
出版事項: (2012-04-01)

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
著者:: Niklas Bergvall, 等
出版事項: (2014-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
著者:: Methma Udawatta, 等
出版事項: (2024-04-01)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis
著者:: Attila Onmez, 等
出版事項: (2013-12-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
著者:: Aaron Boster, 等
出版事項: (2011-09-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
著者:: C. Halasan, 等
出版事項: (2020-01-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
著者:: P Tappenden, 等
出版事項: (2004-06-01)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
著者:: Caporro M, 等
出版事項: (2014-08-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
著者:: Anna Gil-Sánchez, 等
出版事項: (2024-04-01)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
著者:: Anne Waschbisch, 等
出版事項: (2011-01-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
著者:: Genaro Gabriel Ortíz, 等
出版事項: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
著者:: Arielle Kasindi, 等
出版事項: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
著者:: Arthur Komlosh, 等
出版事項: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
著者:: Ioana S. Barac, 等
出版事項: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
著者:: T. E. Shmidt
出版事項: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
著者:: Ignacio Casanova, 等
出版事項: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
著者:: Justin M. Honce, 等
出版事項: (2020-09-01)